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Abstract 
Background: Broadly neutralizing antibodies to HIV-1 elicited in infected individuals evolves through shifts in their 
molecular specificities to viral envelope (Env) in the disease course. Recently, we showed that resistance of circulating 
HIV-1 clade C to the autologous plasma obtained from one Indian elite neutralizer is associated with mutations in V1 
loop. In the present study, we examined the genetic attributes associated with exceptional sensitivity of pseudovi-
ruses expressing an env gene obtained from the follow up visit contemporaneous plasma of the same donor.
Results: Examination of chimeric autologous Envs, we found that enhanced neutralization sensitivity is associated 
with mutations in the V3/C3 region. A positive association between V3/C3 mutation mediated enhanced autologous 
neutralization of autologous viruses with their sensitivity to both neutralizing and non-neutralizing monoclonal 
antibodies was found. Interestingly, we found that depletion of autologous plasma with trimeric and monomeric 
Envs conferred the sensitive Env with resistance indicating that mutations in V3/C3 region altered Env conformation 
towards optimal exposure of epitopes targeted by the neutralizing and non-neutralizing antibodies.
Conclusion: In summary, we found distinct vulnerabilities associated with evasion of circulating viruses to broadly 
neutralizing antibodies mounted in an Indian elite neutralizer.
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Background
Vulnerabilities associated with shift in molecular specifi-
cities of the broadly neutralizing antibodies elicited in a 
small proportion of the Human Immunodeficiency Virus 
Type 1 (HIV-1) infected individuals (also known as elite 
neutralizers) in natural infection provide vital informa-
tion of host-virus interaction towards developmental 
pathway of protective antibodies [1–4]. The HIV-1 uses 
its surface trimeric envelope (Env) protein composed of 
three heterodimers of gp120 and gp41 subunits attached 
non-covalently for viral entry via interaction with CD4 
receptor present on T cells. These Env glycoproteins are 
heavily glycosylated and are targets of the neutralizing 
antibodies. Although HIV-1 infected individuals typically 
develop type-specific autologous neutralizing antibodies 
[5–7], however rarely few of them move on to develop 
cross-neutralizing antibodies [8–12]. It is believed that 
a better understanding of immune evasion mechanisms 
and events leading to development of broadly neutral-
izing antibodies in natural infection would rationally 
inform effective Env based immunogen design that can 
elicit protective antibodies upon vaccination [3].
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Recently in an IAVI Protocol G study, by examining 
Envs obtained from broadly cross neutralizing (BCN) 
plasma of an elite neutralizer (G37080) collected at two 
different time points and spaced between 8 months, we 
showed that mutations in the V1 loop was associated 
with autologous neutralization escape [13]. In the pre-
sent study, we examined an HIV-1 clade C Env (HVTR-
PG80v2.eJ7) obtained from the follow up plasma of the 
same donor (G37080) that significantly differed in its sen-
sitivity to the contemporaneous autologous plasma anti-
bodies compared to the two contemporaneous resistant 
Envs (HVTR-PG80v2.eJ38 and HVTR-PG80v2.eJ41). The 
enhanced sensitivity of pseudoviruses expressing HVTR-
PG80v2.eJ7 Env to the contemporaneous autologous 
broadly neutralizing plasma antibodies was found to be 
associated with mutations in the V3/C3 region and expo-
sure of discontinuous epitopes targeted by neutralizing 
antibodies with multiple specificities.
Methods
Ethics statement
The blood samples were collected under the IAVI Proto-
col G study as described before [13] following approval 
and clearance from the Y R Gaitonde Care, Chennai 
Institutional Review Board (IRB) and the Ethics Com-
mittee. The informed consents were obtained from the 
participating donors to use the samples for assessing neu-
tralizing antibody responses and publishing data keeping 
anonymity of every donor. The serum and plasma sam-
ples collected were shipped to the HIV Vaccine Transla-
tional Research Laboratory, Translational Health Science 
and Technology Institute for further assessment and 
research on the neutralizing antibody response.
Plasmids, viruses, antibodies, proteins and cells
Plasmids encoding patient (G37080) derived HIV-1 enve-
lopes representing distinct clades were described previ-
ously [13]. TZM-bl cells and monoclonal antibodies were 
obtained from the NIH AIDS Research Reagents Refer-
ence program and from the IAVI Neutralizing Antibody 
Consortium (NAC). 293T cells were obtained from the 
American Type Culture Collection (ATCC). Purified 
BG505-SOSIP.664-D7324 protein was kindly provided 
by Prof John Moore, Weill Cornell Medical College, New 
York.
Depletion of plasma antibodies by monomeric, trimeric 
Env proteins and MPER peptide
The depletion of the G37080 BCN plasma with soluble 
Env proteins and MPER peptide was done as described 
previously [13]. Briefly, 30  mg of beads were used to 
couple with 1  mg of both monomeric (4-2.J41) and tri-
meric Env (BG505-SOSIP.664) proteins and 0.5  mg of 
MPER peptide (C1C) in coupling buffer (0.1M NaBO4, 
1M (NH4)2SO4; pH 9.4) overnight at 37  °C for 16–24 h. 
Beads bound to Env proteins were next incubated with 
blocking buffer [PBS (pH 7.4), 0.1 % bovine serum albu-
min (BSA; Sigma) and 0.05 % Tween 20] at 37 °C to block 
the unbound sites. For depletion studies, G37080 visit 2 
plasma was diluted to 1:50 in DMEM containing 10  % 
Fetal Bovine Sera (FBS) and 500  µl of diluted plasma 
was incubated with 20  µl of beads at room tempera-
ture. Unbound plasma antibodies were separated from 
ones those are bound to protein coated beads using a 
DynaMag™ 15 magnet as described previously [13]. This 
step was repeated 4–5 times for depletion of plasma anti-
bodies by monomeric gp120 and 10–12 times in case of 
BG505-SOSIP.664 coated beads respectively.
Neutralization assay
Neutralization assays were carried out using TZM-bl 
cells as described before [13]. Env-pseudotyped viruses 
were incubated with varying dilutions of depleted plasma 
antibodies and incubated for an hour at 37 °C CO2 incu-
bator under humidified condition and subsequently 
1  ×  104 TZM-bl cells were added into the mixture in 
presence of 25  μg/ml DEAE-dextran (Sigma, Inc.).The 
plates were further incubated for 48 h and the degree of 
virus neutralization was assessed by measuring relative 
luminescence units (RLU) in a Luminometer (Victor X2, 
PerkinElmer Inc.). All the neutralization assays were done 
in duplicate and repeated at least two times. The effect of 
point substitutions on neutralization of Env-pseudotyped 
viruses (as shown in Table 2) were done in triplicates and 
was repeated three times. A fold change in neutraliza-
tion titer (ID50) (due to amino acid substitution/s) that is 
equal to or greater than twofold (≥twofold) in our study 
was considered positive.
PCR amplification, cloning and mutagenesis of autologous 
env
Autologous env clones were obtained from G37080 
plasma by limited dilution PCR with slight modification 
to the methodology described previously [14]. Briefly, 
viral RNA were extracted using High Pure viral RNA 
kit (Roche Inc.) following manufacturer’s protocol and 
cDNA prepared by RT-PCR using Superscript-III first 
strand synthesis kit (Invitrogen Inc.). rev-gp160 env genes 
were amplified from the maximally diluted plasma sam-
ple using a Phusion hi fidelity DNA polymerase (New 
England Biolabs Inc.). The complete env gene was puri-
fied and ligated into pcDNA 3.1/V5-His-TOPO (Invitro-
gen Inc.) vector. Chimeric Envs were prepared (Fig.  2a) 
by overlapping PCR and point substitutions were made 
by Quikchange II kit (Agilent technologies Inc.) following 
manufacturer’s protocol and as described previously [13].
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Preparation of Env‑pseudotyped viruses
Pseudotyped viruses were prepared by co-transfection 
of envelope expressing plasmid with env-deleted HIV-1 
backbone plasmid (pSG3ΔEnv) into 293T cells in 6-well 
tissue culture plates using FuGENE6 Transfection 
Reagent (Promega Inc). Cell supernatants containing 
pseudotyped viruses were used subsequently in neutrali-
zation assays in TZM-bl cells. The reduction of infec-
tion of TZM-bl cells by the Env-pseudotyped viruses 
were determined by measuring luciferase activity using 
Britelite luciferase substrate (Perkin Elmer) with a Victor 
X2 Luminometer (Perkin Elmer).
Results and discussion
An HIV‑1 clade C Env obtained from broadly neutralizing 
plasma showed exceptional degree of sensitivity 
to contemporaneous and retrospective autologous plasma 
antibodies
We recently reported [13] pseudoviruses expressing 
env genes obtained from follow up plasma of an Indian 
elite neutralizer (G37080) those were found to be resist-
ant to their contemporaneous autologous plasma anti-
bodies. We subsequently amplified a functional env 
(gp160) gene (HVTR-PG80v2.eJ7) by PCR from the same 
plasma, which when expressed as Env-pseudotyped virus 
showed exceptional sensitivity to its contemporane-
ous autologous plasma antibodies in sharp contrast to 
its contemporaneous autologous Envs (HVTR-PG80v2.
eJ38 and HVTR-PG80v2.eJ41) (Fig.  1a). Additionally, 
HVTR-PG80v2.eJ7 unlike HVTR-PG80v2.eJ38 and 
HVTR-PG80v2.eJ41 Envs was also found to be sensitive 
to plasma antibodies collected at prior time point (data 
not shown). Analysis of gp160 sequence revealed that 
PG80v2.eJ7 is an HIV-1 clade C Env (http://www.bioaf-
rica.net/rega-genotype/html/) and found to cluster with 
contemporaneous Envs revealing close genetic related-
ness compared to Envs obtained at previous time point 
(Fig. 1b). Comparison of amino acid sequences revealed 
that except for intermittent differences in the V3–C4 
and V5 regions, HVTR-PG80v2.eJ7 Env was found to 
be genetically identical to the other two contemporane-
ous autologous Envs (HVTR-PG80v2.eJ38 and HVTR-
PG80v2.eJ41) (Fig.  1c). Interestingly, when compared 
with all the autologous env sequences obtained from both 
visit 1 and visit 2, HVTR-PG80v2.eJ7 showed >97 % simi-
larity in its amino acid composition (Table 1), indicating 
that in addition of this Env having conserved structure 
and function with that of other autologous Envs, it is 
also clonally and closely related to them (as shown in 
Fig. 1b), which possess unique property associated with 
its enhanced susceptibility to autologous BCN plasma 
antibodies. Overall, we identified an HIV-1 clade C Env 
obtained from plasma with exceptional breadth which 
displayed exceptional sensitivity to its contemporaneous 
autologous plasma, a property which is atypical of cir-
culating viruses in presence of strong humoral immune 
response.
V3/C3 region conferred resistant autologous Env 
with enhanced sensitivity to contemporaneous plasma 
antibodies
To examine whether differences in the amino acid 
sequences accounts for resistance of autologous Envs to 
the contemporaneous autologous plasma antibodies, we 
prepared chimeric Envs by replacing V3/C3, V3–C4, C4–
C5 and gp41 regions of the resistant Env (HVTR-PG80v2.
eJ38) with that of the sensitive Env (HVTR-PG80v2.
eJ7) (Fig.  2a). Pseudoviruses expressing chimeric Envs 
were then examined for their degree of susceptibility to 
the contemporaneous autologous plasma antibodies. 
As shown in Fig.  2b, both V3/C3 and V3–C4 chimeras 
conferred the HVTR-PG80v2.eJ38 Env with enhanced 
sensitivity by >400 and >130-folds respectively to the 
contemporaneous autologous plasma. Comparable data 
was found when serum IgG was tested (Fig.  2c). Inter-
estingly, a difference in V5 sequence between the Envs 
(Fig.  1c) was not found to be associated with neutrali-
zation susceptibility. Our data suggested that residues 
incorporated from the sensitive HVTR-PG80v2.eJ7 Env 
altered conformation of the HVTR-PG80v2.eJ38 Env that 
facilitated autologous plasma antibodies towards com-
prehensive virus neutralization. Although, we do not rule 
out the possibility that the plasma antibodies targeted 
the amino acid residues in the V3 region of the sensitive 
chimeric envelope; however, when compared, minimal 
changes between the V3 amino acid sequences of the 
autologous Envs obtained from both the visits (Fig.  3). 
The enhanced sensitivity of the v2.eJ38 (v2.eJ7 V3/C3) 
envelope similar to tier 1 viruses (which in its wild type 
was found to be resistant to autologous neutralization) 
due to the V3/C3 residues brought from its contempo-
raneous envelope possibly form epitopes targeted by the 
plasma antibodies. Comparable data were obtained when 
the chimeric viruses were tested against the contempo-
raneous serum IgG (Fig.  2b), suggesting the neutraliza-
tion that we observed was indeed antibody mediated. 
Since substitution of amino acid residues in the V3/C3 
domain conferred HVTR-PG80v2.eJ38 Env with maxi-
mal sensitivity to the autologous BCN plasma, we further 
examined whether specific residues within this region 
significantly modulated the neutralization susceptibility 
of the HVTR-PG80v2.eJ38 by fine mapping. As shown 
in Table  2, only P326I substitution in the V3 loop was 
found to show >eightfold increase in neutralization of 
HVTR-PG80v2.eJ38, while none other amino acid resi-
dues that differed between the sensitive HVTR-PG80v2.
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eJ7 and the resistant HVTR-PG80v2.eJ38 and HVTR-
PG80v2.eJ41 Envs were found to contribute in modulat-
ing virus neutralization. Although P326I substitution 
conferred the HVTR-PG80v2.eJ38 Env with increase in 
its autologous neutralization susceptibility by >eightfold, 
it partially restored its neutralization sensitivity. Our data 
indicates that although P326I had a major effect, pres-
ence of other residues in the V3–C4 region in addition 
to I326 were associated towards achieving comparable 
neutralization susceptibility of chimeric Envs to that of 
the wild type. Interestingly, except HVTR-PG80v2.eJ7, 
none of the autologous Envs obtained from the G37080 
donor at two different time points were found to contain 
the N332 glycan [13]. Additionally, N332T substitution 
(Table  2) in the v2.eJ7 Env did not alter their suscepti-
bilities to the contemporaneous autologous antibodies, 
indicating that autologous plasma do not have antibod-
ies that target this glycan epitope. We further examined 
whether presence of the glycan residues N360 in v2.eJ7 
Fig. 1 a Neutralization of HIV-1 Envs to contemporaneous autologous G37080 BCN plasma. b Genetic relatedness of autologous Envs obtained 
from the plasma of the G37080 donor at two different time points. Maximum likelihood phylogenetic tree was constructed using the amino acid 
sequences of the viral Envs using Mega 5.1 version. c Alignment of the V3–C4 amino acid sequences of the contemporaneous Envs obtained at the 
same time point
Table 1 Similarity of amino acid sequence of PG80 v2.eJ7 
env with that of other autologous envs
LALIGN tool (http://www.ch.embnet.org/software/LALIGN_form.html) was used 
to obtain sequence identity and similarity
a ‘% identity’ refers to the degree of correlation between two un-gapped 
sequences and indicates that the amino acid at the particular position is an 
exact match
b ‘ % similarity’ refers to the degree of resemblance between two sequences and 
indicates that the amino acids at a particular position have some properties in 
common (e.g., charge or hydrophobicity) but are not identical
Donor visit # Autologous envs % Identitya % Similarityb
Visit # 2 PG80v2.eJ7 100.0 100.0
PG80v2.eJ38 95.7 98.0
PG80v2.eJ41 95.3 98.0
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and N362 in v2.eJ38 Envs in the C3 region were associ-
ated with enhanced neutralization sensitivity and resist-
ance respectively as these residues were uniquely present 
in these two Envs only and not to other autologous Envs 
obtained from visit 1 plasma of the G37080 donor. As 
shown in Table 2, we did not find any association of these 
glycan residues with altered susceptibility of the Envs to 
autologous plasma antibodies. Interestingly, we further 
observed that the HVTR-PG80v2.eJ38 chimeric Env (V3/
C3 chimera) became resistant to the autologous G37080 
BCN plasma depleted with BG505-SOSIP.664 soluble 
trimeric protein (Table 3), indicating that the shift in the 
neutralization susceptibility of the resistant PG80v2.eJ38 
Env to its autologous plasma was associated with expo-
sure of epitopes targeted by both neutralizing antibodies 
and non-neutralizing antibodies.   
Changes in V3/C3 sequence conferred autologous Envs 
vulnerable to neutralizing and non‑neutralizing mAbs
We next examined the association of neutralization sen-
sitivity of the autologous Envs including the chimeric 
Envs with their degree of sensitivities to monoclonal anti-
bodies with distinct targets. As shown in Table 4, HVTR-
PG80v2.eJ7 wild type Env was found to be sensitive to 
Fig. 2 a Construction of chimeric Envs using HVTR-PG80v2.eJ38 as backbone. The positions between which the fragments of the HVTR-PG80v2.eJ7 
Env were substituted were highlighted. The degree of neutralization sensitivities of the wild types and the chimeric Envs to the contemporaneous 
autologous plasma (b) and serum IgG (c) are shown
Fig. 3 V3 loop amino acid alignment of the autologous envs
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broadly neutralizing (such as VRC01, PG9, PGT128, 
PGT135, 10E8), those targeting V3 loop with limited 
breadth (such as 3074 and 3869), non-neutralizing (b6, 
F105) and coreceptor binding site (CoRbs) (17b) directed 
mAbs. On the other hand, the HVTR-PG80v2.eJ38 
wildtype was found to be resistant to most of the neutral-
izing, non-neutralizing and CoRbs directed mAbs. How-
ever, fragments of the HVTR-PG80v2.eJ7 Env displayed 
similar neutralization sensitivity to all the neutralizing 
and non-neutralizing monoclonal antibodies, suggest-
ing that V3–C4 domain was responsible for exposure of 
discontinuous epitopes that are targets of neutralizing 
and non-neutralizing antibodies. HVTR-PG80v2.eJ7 
is the only autologous Env which was found to contain 
N332 in the V3 base compared to all other autologous 
Envs that contains T332 and hence, compared to its wild 
type, the HVTR-PG80v2.eJ38 Env containing V3/C3 and 
V3–C4 regions of the HVTR-PG80v2.eJ7 Env were found 
to restore its sensitivity to PGT121. Interestingly, while 
HVTR-PG80v2.eJ38 (V3/C3 chimera) despite express-
ing N332 was found to be resistant to the PGT128 and 
PGT135 mAbs, HVTR-PG80v2.eJ38 Env (expressing V3–
C4 of HVTR-PG80v2.eJ7) conferred the HVTR-PG80v2.
eJ38 Env susceptible to these two mAbs, indicating resi-
dues within V3–C4 of the sensitive HVTR-PG80v2.eJ7 
Env modulated the conformation of the resistant HVTR-
PG80v2.eJ38 Env for optimal exposure of epitopes tar-
geted by PGT128 and PGT135 for comprehensive virus 
neutralization. The CATNAP database (HIV Los Alamos 
database; www.hiv.lanl.gov) provides information on the 
residues that form epitopes for several broad and potent 
monoclonal antibodies to HIV-1. Accordingly, the follow-
ing residues are important for PGT128/PGT135 mAbs: 
N301/T303/R304/I323/G324/N325/M326/R327/N332. 
We found that both the HVTR-PG80v2.eJ7 (sensitive 
to autologous neutralization) and the HVTR-PG80v2.
eJ38 (resistant to autologous neutralization) contains all 
Table 2 Mapping amino acid residues in the V3/C3 region 
associated with neutralization sensitivity
* The T362N/A364S double mutations removed the N360 glycan and introduced 
N362 glycan in PG80v2.eJ7 Env
Potential N-linked glycans are given in italic
Env‑pseudotyped viruses (Env 
chimeras & point mutants)
Fold changes in ID50 Effect
HVTR-PG80v2.eJ7 wild type – –
HVTR-PG80v2.eJ38 wild type – –
HVTR-PG80v2.eJ38(v2.eJ7V3/C3) >422 Increase
HVTR-PG80v2.eJ38(v2.eJ7V3-C4) >138 Increase
HVTR-PG80v2.eJ38(v2.eJ7gp41) 0.8 No change
HVTR-PG80v2.eJ38(I307F) 1 No change
HVTR-PG80v2.eJ38(M316A) 1 No change
HVTR-PG80v2.eJ38(P326I) >8 Increase
HVTR-PG80v2.eJ38(N362T) 1 No change
HVTR-PG80v2.eJ7(N332T) 1.2 No change
HVTR-PG80v2.eJ7(E328Q) 1.8 Decrease
HVTR-PG80v2.eJ7(T362N/A364S)* 1.0 No change
Table 3 Effect of depletion of G37080 BCN plasma antibodies on autologous virus neutralization
Fold reduction in virus neutralization was obtained by comparing the neutralization titer (ID50 values) of Env-pseudotyped viruses against undepleted and depleted 
G37080 plasma. ID50 values are reciprocal dilutions at which the undepleted and depleted plasma conferred 50 % neutralization of the Env-pseudotyped viruses in 
TZM-bl cells. ‘v1’ and ‘v2’ refers to Envs obtained from visit 1 and visit 2 plasma samples
G37080 depleted plasma (fold reduction in ID50)
Env‑pseudotyped viruses gp140 Trimer (BG505‑SOSIP.664) gp120 Monomer (4‑2.J41) MPER (C1C peptide) References
HVTR-PG80v2.eJ7 >150.0 80.0 1.00 This study
HVTR-PG80v2.eJ38 (v2.eJ7V3/C3) >70.0 >10.0 1.10 This study
HVTR-PG80v1.eJ7 >10.03 0.9 1.12 [13]
HVTR-PG80v1.eJ19 >15.60 0.5 1.18 [13]
92BR020 >35.08 1.1 1.34 [13]
Table 4 Sensitivity of autologous Envs to mAbs
Envs and chimeras CH01 b12 VRC01 sCD4 b6 F105 17b PG9 PG16 PGT145 PGT121 PGT128 PGT135 3074 3869 PGT151 4E10 10E8
PG80v1.e7 >5 >5 0.09 >5 >25 >25 >25 0.15 >5 >10 >5 >5 >5 >10 >10 >5 >5 0.65
PG80v1.e19 >5 >5 0.21 >5 >25 >25 >25 2.41 >5 0.24 >5 >5 >5 >10 >10 >5 >5 4.47
PG80v2.e7 >5 >5 0.53 <0.2 0.3 <0.2 2.34 0.18 >5 >10 >5 0.9 3.55 <0.078 0.14 >5 2.18 0.04
PG80v2.e38 >5 >5 0.13 2 >25 >25 >25 <0.078 >5 >10 >5 >5 >5 >10 >10 >5 >5 0.93
PG80v2.eJ38 (v2.eJ7V3C3) >5 >5 2.09 <0.2 4.73 >25 7.97 <0.078 >5 >10 1.69 >5 >5 <0.078 1.58 >5 4.59 0.18
PG80v2.eJ38 (v2.eJ7V3C4) >5 >5 3.6 <0.2 7.19 >25 23.46 <0.078 >5 >10 0.99 0.11 0.32 <0.078 <0.078 >5 >5 0.28
Values are mAb doses (µg/ml) at which 50 % virus neutralization are observed in TZM-bl cells. IC50 values less than 1, 3 and 5 µg/ml are highlighted in red, orange and 
light pink respectively
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these residues with following exceptions: (1) PG80v2.
eJ38 lacks N332 residue as pointed above), (2) N325 is 
absent in both the PG80v2.eJ7 and PG80v2.eJ38 enve-
lopes; both contains D325 (aspartic acid) and (3) M326 is 
absent in both the envelopes; while PG80v2.eJ7 contains 
I326 (an isoleucine residue), the PG80v2.eJ38 envelope 
contains P326 (a proline residue). Interestingly, neither 
the PG80v2.eJ38 envelope nor its chimera (express-
ing the V3/C3 domain of the PG80v2.eJ7 envelope) was 
found to show modest resistance to the PGT128/PGT135 
mAbs. On the other hand, the PG80v2.eJ38 chimeric 
envelope expressing V3–C4 domain of the PG80v2.eJ7 
envelope was found to show sensitivity to both PGT128 
and PGT135 mAbs, suggesting that while V3/C3 swap 
conferred the resistant PG80v2.eJ38 envelope with expo-
sure of epitopes that are targeted by the non-neutraliz-
ing antibodies e.g., b6, 17b, V3 directed mAbs (3074 and 
3869) including those present in the autologous plasma; 
however the V3–C4 swap enabled optimal exposure 
of neutralizing epitopes targeted by potent and broadly 
neutralizing antibodies such as PGT128 and PGT135. 
Overall, our data indicate that subtle changes in V3–C4 
region is capable of concealing key epitopes associated 
with broad neutralization which recognizes PGT128 and 
PGT135 like mAbs by altering Env conformations.
Association of presence of D167 in V2 apex with resistance 
to the PGT145 mAb
Additionally, we found that except for HVTR-PG80v1.
eJ19 (obtained from visit 1 plasma) [13], all the autolo-
gous Envs obtained from both visit plasma were resistant 
to PGT145 mAb. Interestingly, we found that the pres-
ence of G167 residue in all the autologous Envs (except 
the HVTR-PG80v2.eJ19 Env, which was found to possess 
D167) was found to be correlated with their resistance to 
PGT145 mAb. A G167D substitution was found to con-
fer the autologous Envs sensitive to PGT145 mAb with 
IC50 value of <0.04  µg/ml (Fig.  4). This is an interesting 
observation since G167 amino acid residue forms one of 
the epitopes for PGT145 mAb recognition in majority of 
the HIV-1 strains (www.hiv.lanl.gov) and no association 
of mutation of this residue with PGT145 resistance was 
reported. Our data contribute information to the reper-
toire of knowledge of mechanism modulating the sensi-
tivity of HIV-1 to the cleavage-dependent bnAb, PGT145.
Conclusion
In summary, we report an HIV-1 clade C Env (HVTR-
PG80v2.eJ7) from the G37080 BCN plasma of an elite 
neutralizer of Indian origin which displayed exceptional 
sensitivity to its contemporaneous autologous plasma 
antibodies. The HVTR-PG80v2.eJ38 resistant Env 
expressing the V3/C3 sequence of the HVTR-PG80v2.eJ7 
Env was found to accommodate conformational epitopes 
targeted by the neutralizing antibodies present in the 
G37080 plasma as evident by the BCN plasma depletion 
study. Overall, we found that initially while the viruses 
circulating early escaped from the broadly neutraliz-
ing autologous antibodies via mutations in V1 loop that 
we recently reported [13], they subsequently evaded the 
antibody pressure in the disease course by accommodat-
ing mutations in V3/C3 region. Understanding pathways 
of co-evolution of circulating virus and neutralizing anti-
bodies specific to them will complement strategies of 
rational immunogen design towards achieving elicitation 
of antibodies with similar breadth and potency.
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